Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding Stelara impact. However, J&J faces headwinds from Stelara's patent expiration, MedTech slowdown, and upcoming generic competition for other drugs. Despite these challenges, analysts recommend staying invested given the company's diversified portfolio, strong pipeline, and confident guidance.

The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.

Johnson & Johnson demonstrates resilience during market downturns, with shares falling less than 2% while the S&P 500 dropped over 7%. The healthcare giant maintains strong fundamentals including 63 consecutive years of dividend increases, $94.2 billion in 2025 revenue (up 6%), and 51 drug approvals last year. However, the stock faces headwinds from tens of thousands of talc-related lawsuits and Medicare drug price negotiations under the Inflation Reduction Act.

The FDA approved Icotyde (icotrokinra), an oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis developed by Johnson & Johnson and Protagonist Therapeutics. The approval triggers a $50 million milestone payment to Protagonist with potential for up to $580 million in additional payments. AbbVie's stock fell 5.20% as analysts view Icotyde as competitive to AbbVie's Skyrizi, though both companies believe oral therapies could expand the overall psoriasis market.

Hedge fund BVF fully exited its position in Protagonist Therapeutics (PTGX), selling 2.56 million shares worth $170.12 million. Despite the stock rallying 120% over the past year, the fund's exit reflects a disciplined capital rotation strategy following the company's New Drug Application submission for rusfertide in polycythemia vera, marking a shift from clinical-stage risk to regulatory execution risk.

Moody Aldrich Partners LLC completely sold its entire 35,228 share position in Chart Industries, valued at approximately $5.8 million, reducing its reportable assets to zero in Q3 2025.

Moody Aldrich Partners LLC completely sold its entire 53,211 share position in Palomar Holdings for an estimated $8.21 million during Q3 2025, reducing its stake to zero, likely as part of routine portfolio rebalancing.

Johnson & Johnson demonstrated strong financial health in Q3, with 7% sales growth, $14.2 billion in free cash flow, and plans to separate its orthopedics business to focus on six priority growth areas. The company remains committed to dividend growth and oncology investments.

Johnson & Johnson reported strong Q3 2025 earnings, beating consensus estimates, and announced plans to separate its Orthopedics business into a standalone entity called DePuy Synthes within 18-24 months, targeting increased top-line growth and operating margins.

The FDA updated safety labeling for Johnson & Johnson's Carvykti cancer cell therapy, adding a warning about immune effector cell-associated enterocolitis, a serious complication with potential fatal outcomes. Despite the warning, regulators affirmed the therapy's benefits continue to outweigh its risks.

Douglas Lane & Associates increased its Johnson & Johnson stake by 34,948 shares, worth approximately $6 million in Q3, bringing total holdings to 667,373 shares valued at $123.7 million. The investment comes ahead of J&J's earnings report and potential biotech acquisition of Protagonist Therapeutics.